3 Semaglutide (Wegovy) Efficacy: In the STEP 1 trial involving adults with overweight or obesity without diabetes, those taking Wegovy 2.4 mg once weekly for 68 weeks achieved an average weight loss of approximately 14.9%, compared to 2.4% in the placebo group
Some experts have argued that this was an unfair comparison: if the full 2.4 mg dose of semaglutide had been administered, the difference could have been smaller [2]
[11] In practice, sermorelin is almost never used during pregnancy, since treating chronic growth hormone deficiency can typically be deferred and other therapies (if needed) would be chosen if GH support was truly required
Key Takeaways of the Global Tirzepatide Market Type 2 diabetes holds the largest market share by indication, accounting for an expected in 2026, due to the growing global prevalence of type 2 diabetes
The oral vs injection comparison explores the bioavailability differences and what oral dosing at equivalent efficacy levels might look like